Organogenesis Reports Steep Q1 Revenue Decline and Widened Loss Amid Restructuring, Achieves Positive Operating Cash Flow

summarizeSummary

Organogenesis Holdings Inc. reported a significant 57% year-over-year revenue decline and a widened net loss in Q1 2026, primarily due to adverse CMS reimbursement changes. The company initiated a restructuring plan, including a 10% workforce reduction and facility closure, but achieved positive operating cash flow and confirmed a 12-month liquidity runway.

check_boxKey Events

• Q1 2026 Financial Performance

  Total revenue decreased by 57% year-over-year to $37.2 million, and net loss widened to $53.2 million from $18.8 million in Q1 2025. Basic EPS was $(0.44) compared to $(0.17) in the prior year.

• Advanced Wound Care Revenue Decline

  Net product revenue in the Advanced Wound Care segment dropped by 63% year-over-year, primarily attributed to market disruption and clinician confusion following adverse CMS reimbursement changes and comments on discarded product.

• Restructuring Plan Initiated

  The company committed to a restructuring plan in March 2026, reducing headcount by 88 employees (approximately 10% of the workforce) and closing its St. Petersburg, Florida facility. This resulted in an $8.8 million charge, including severance and asset write-downs.

• Positive Operating Cash Flow

  Net cash provided by operating activities was $21.1 million in Q1 2026, a significant improvement from a $19.9 million usage in Q1 2025, driven by a substantial decrease in accounts receivable.

auto_awesomeAnalysis

Organogenesis Holdings Inc.'s Q1 2026 results reflect a challenging operating environment, with a substantial 57% year-over-year revenue decline and a significantly widened net loss. This downturn is largely driven by the previously disclosed adverse CMS reimbursement changes and market confusion impacting its Advanced Wound Care segment. In response, the company has initiated a restructuring plan, including a 10% workforce reduction and facility closure, aiming to improve efficiency and profitability. While these measures indicate significant operational challenges, the company's ability to generate $21.1 million in positive operating cash flow, primarily through effective working capital management (notably a large reduction in accounts receivable), is a critical positive signal. This, combined with $91.4 million in cash and an available $75.0 million revolving facility, provides a confirmed liquidity runway for at least the next 12 months, mitigating immediate solvency concerns. The completion of the ReNu BLA submission is a positive regulatory milestone for future product development. Investors should monitor the effectiveness of the restructuring efforts and the company's ability to stabilize revenue in subsequent quarters, particularly as the market adapts to the CMS changes. The new executive retention agreements suggest a focus on leadership stability during this transitional period.